Cancer diagnostics company reveals Medicare's coverage accounted for 77% of its total operating revenue in 2023. Over the coming days Pacific Edge will explore all available legal options. Dual-listed cancer diagnostics company Pacific Edge is 'surprised and disappointed' by a decision which will see its Cxbladder tests no longer covered by US national health insurance provider Medicare, and says it is exploring all legal options. The company has also confirmed that Medicare's Want to read more? It's easy.

https://www.nbr.co.nz/investment/pacific-edge-surprised-disappointed-mulls-legal-action/

#nbr